Abstract:Selection of the treatments most likely to combat a patient's tumor is a central aim of precision oncology. We are currently developing a functional precision oncology program at the University of Utah and Huntsman Cancer Institute that combines the multi-omic characterization of a patient's tumor with the functional screening of relevant drug candidates in patient-derived organoid tumor models to identify which drugs are uniquely capable of combating the patient's cancer. Here we present our model-based approach for utilizing the multi-omic tumor data to computationally predict the patient's response to each drug. In this approach, we first identify the genomic and transcriptomic vulnerabilities of the tumor as genes harboring somatic DNA mutations or copy number changes (from paired tumor/normal WGS/WES DNA sequencing data), as well as genes whose expression levels have been significantly altered in the tumor (based on bulk or single-cell RNA sequencing data). Second, using targeting information from drug-gene interaction databases (DGIdb) we compile a list of genes targeted by each drug relevant in the patient's treatment. Third, we utilize gene interaction database knowledge (KEGG) to construct a gene interaction graph to link each drug's gene targets with all of the tumor's vulnerability genes. We then identify all gene interaction paths connecting specific drug target genes with specific vulnerability genes; and score each path and combine all path-specific scores for the target-vulnerability gene pair. Subsequently, we further combine all pairwise scores across all drug target genes and all tumor vulnerability genes and determine the statistical significance of the resulting score by sampling the background distribution of such scores across random drugs, target genes, and vulnerability genes. We have applied our algorithm to predict drug response in advanced breast cancer patients as well as using publicly available tumor cell line data (GDSC2). We have found a high level of concordance between our computational prediction and organoid/cell line screening results, clearly separating sensitive and non-sensitive models. Using Bayesian probability, we compare the drug-specific score distributions of sensitive and non-sensitive models and are able to identify sensitive cell lines/patients with high accuracy. By encapsulating available information on direct gene-gene interactions, the drug's direct gene targets and the collected omic vulnerabilities of the tumor, our model is not only capable of predicting sensitivity to both targeted and chemotherapy agents, but can also provide a mechanistic understanding for the targeting of the tumor. Our approach will be validated and fine-tuned on a large cohort of breast and brain cancer patients as well as patient PDX models, interrogating gene-target interactions to identify novel relevant target genes/pathways. Citation Format: Szabolcs Tarapcsak, Yi Qiao, Xiaomeng Huang, Tony Di Sera, Matthew H. Bailey, Bryan E. Welm, Alana L. Welm, Gabor T. Marth. Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2723.

Learning and actioning general principles of cancer cell drug sensitivity

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Systematic identification of genomic markers of drug sensitivity in cancer cells

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

A comprehensive benchmarking of machine learning algorithms and dimensionality reduction methods for drug sensitivity prediction

A community effort to assess and improve drug sensitivity prediction algorithms

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

Personalised Medicine: Establishing predictive machine learning models for drug responses in patient derived cell culture

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

A Comprehensive Investigation of Active Learning Strategies for Conducting Anti-Cancer Drug Screening

Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs

Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

Pre-Training on In Vitro and Fine-Tuning on Patient-Derived Data Improves Deep Neural Networks for Anti-Cancer Drug-Sensitivity Prediction

Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining